• 中国资本市场开放出大招 跨境证券投资更便利 2019-10-13
  • 世卫将“游戏障碍”列为新疾病 哪些症状可被确诊? 2019-10-13
  • 景区去门票化积弊短期难除 如何摆脱门票依赖? 2019-10-08
  • 东风路老旧小区欲华丽变身 微改造项目勘察设计已招标 ——凤凰网房产广州 2019-10-08
  • 翔龙无人机服役后首次曝光,大幅提升空军情报收集能力 2019-09-19
  • 证监会去年对外公开监管信息14560条 2019-09-19
  • 人民网欧洲中心分社记者报道集 2019-09-06
  • 图解:短视频平台频遭约谈敲响警钟,野蛮生长要不得! 2019-09-06
  • 中考期间广州部分公交线路有调整 2019-09-01
  • 减肥必备!这十种食物饱口福还能吃出好身材 2019-09-01
  • “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置时时彩网络平台>技术资料首页>行业动态>公司动态>昆泰公司宣布与Movetis公司结为战略联盟,上市胃肠病新药

    拉人玩时时彩的套路: 昆泰公司宣布与Movetis公司结为战略联盟,上市胃肠病新药

    Quintiles2010年2月1日 15:53 点击:2521

    时时彩网络平台 www.qlgr.net 美国昆泰跨国公司 (Quintiles Transnational Corp.)
    协议覆盖慢性便秘用药
    RESolor® (普卢卡必利)在英国、德国和选定欧洲市场的行销

    美国北卡罗来纳州研发三角园区和比利时TURNHOUT -- (美国商业资讯)--昆泰公司(Quintiles)今天宣布与MovetIS公司结为战略联盟,在英国和德国行销Movetis公司的新产品Resolor(普卢卡必利)。根据协议,昆泰将为该产品的上市创建一支配备齐全的商业销售队伍,并在咨询、市场情报及分析、法规和上市后药物安全性监测方面提供额外服务。该协议预计在今年下半年扩展,覆盖其他选定的欧洲国家。

    Movetis公司是一家欧洲药企,针对胃肠病专科治疗领域,专业研发行销专利创新药物。Movetis公司的Resolor获得欧洲经济区的准销许可,用于泻药无法充分缓解的女性慢性便秘的对症治疗。

    昆泰公司全球业务开发和营运高级副总裁Chris Pepler说:"这份协议是领先专科药企构建伙伴关系的典范,这种伙伴关系超越了商业销售组织的传统模式,在风险管理、生产率提升、复杂局面掌控、以及向新卫生体系的攸关方展示价值方面进行了拓展。我们感到欣慰的是,Movetis公司看中并选择了昆泰公司的全套服务,包括本公司的产品及品牌解决方案,藉此保障Resolor的商业成功。"

    Movetis公司首席执行官Dirk Reyn 说:"我们确信与昆泰结盟将推动我们成为一家成功的欧洲胃肠病专科药企的目标。我们的专长是将胃肠病新药由研发带向市场,Resolor上市是这一不断建设过程中一个关键的里程碑。"

    关于Movetis公司

    Movetis公司是一家欧洲药企,针对胃肠病治疗领域未获满足的医药需求,专业研发行销创新的专科用药,以改善亿万成人及儿童患者的生活。Movetis公司于2006年11月在比利时创立,其前身隶属强生医药集团。

    除了Resolor,Movetis公司还拥有品种多样的胃肠病产品线,其中2个正在2期开发中,另有2个优先化合物在临床前开发中,均针对胃肠病重点领域,包括腹水、儿科反流、难治性GERD(胃食管反流?。┖椭刂⒊と亲酆险?。此外, Movetis公司还拥有大容量先导化合物库的产权,这些化合物有望进入开发、针对不同的胃肠病适应证,Movetis公司还掌握着治疗分泌性腹泻的多种化合物的作用机理。该公司现有产品阵容来自于强生集团下属两家公司(比利时杨森公司和Ortho-McNeil制药公司)的授权。Movetis公司的股票在布鲁塞尔EuronEXt挂牌,股票代码是MOVE。

    关于昆泰

    昆泰公司是唯一一家在全球范围内全方位提供临床、商业、咨询及资本解决方案的生物制药服务公司。昆泰在全球50多个国家拥有23,000名勤奋的专业员工,坚定不移地致力于为患者服务、安全?;ず偷赖鹿娣?。昆泰公司帮助生物制药公司在充满变化的环境中驾驭风险并获取机会。欲了解更多信息,请登陆公司网页:www.quintiles.com。

    前瞻性陈述

    本新闻稿包含"前瞻性陈述",其基础是当前对未来事件的各种期望。若基础假设经证实属欠精确,或发生未知风险或不确定因素,则实际结果可能与期望和预测有实质性差异。这些风险和不确定因素包括:业界普遍状况、竞争者取得技术进步和专利、研发及法规流程所固有的挑战、与产品营销相关的挑战,诸如新产品的市场接受度无法预见,患者治疗结果不一致,产品可能失效,潜在的工艺难点,政府法律法规影响国内外经营及合作的持续成功,等等。除非法律要求,各方无意或没有义务更新这些前瞻性陈述,特此声明。

    免责声明:本公告之原文版本乃官方授权版本。译文仅供方便了解之用,烦请参照原文,原文版本乃唯一具法律效力之版本。

    联系方式:

    昆泰

    Mari Mansfield, 媒体关系, 919-998-2639

    [email protected]

    Greg Connors, 投资者关系, 919-998-2000

    [email protected]

    Movetis

    Chris Van Raemdonck, 媒体关系, +32 14 404 239

    [email protected]

    Ingrid Jansen, 媒体关系, +32 14 404 390

    [email protected]

    Quintiles新闻稿

    QUINTILES AND MOVETIS ANNOUNCE STRATEGIC ALLIANCE

     

    Agreement covers chronic constipation therapy Resolor® (prucalopridein) in the U.K., Germany and select European markets

    RESEARCH TRIANGLE PARK, N.C. & TURNHOUT, BELGIUM – January 28, 2010 – Quintiles today announced a strategic alliance with Movetis NV for commercialization of its new product, Resolor (prucalopride), in the U.K. and Germany. Under the alliance, Quintiles will execute a comprehensive commercial sales effort for the product launch and provide additional services in consulting, market access, market intelligence and analytics, regulatory and post-marketing pharmacovigilance. The agreement is expected to be extended later this year to cover other selected European countries.

    Movetis is a European specialty pharmaceutical company focused on the discovery, development and commercialization of proprietary and innovative drugs for the treatment of diseases in the gastrointestinal (GI) area. Movetis obtained approval for the commercialization of Resolor in the European Economic Area for the symptomatic treatment of chronic constipation for women in whom laxatives fail to provide adequate relief.

    Chris Pepler, Senior Vice President of Global Business Development and Operations for Quintiles said: “This agreement is an example of how leading specialty pharma companies are building partnerships that extend beyond the traditional Commercial Sales Organization model to manage risk, increase productivity, overcome complexity and demonstrate value to stakeholders in the New Health. We are pleased that Movetis has chosen to leverage Quintiles’ suite of comprehensive services, including our product and brand solutions, to help ensure the commercial success of Resolor.”

    Movetis CEO Dirk Reyn said: “We are confident that our alliance with Quintiles will help drive our goal of becoming a successful European specialty GI company. The launch of Resolor will be a key milestone as we continue to build on our expertise in bringing new GI drugs from discovery to marketing.”

    About Movetis
    Movetis is a European specialty GI company that is focused on improving the lives of millions of patients – both adults and children – by discovering, developing and commercializing innovative treatments targeting GI conditions with a high unmet medical need. Movetis NV was founded in Belgium in November 2006 as a spin-off of Johnson & Johnson.

    In addition to Resolor, Movetis has a broad portfolio of GI products: two products are in Phase II development and Movetis has two prioritized compounds in preclinical development, all addressing important GI areas including ascites, pediatric reflux, refractory GERD (gastroesophageal reflux disease) and severe forms of irritable bowel syndrome. In addition, Movetis has rights to a large library of qualified lead compounds with potential for development in different GI indications, and access to know-how for compounds in secretory diarrhoea. The current portfolio is licensed from Janssen Pharmaceutica NV, Belgium and Ortho-McNeil Pharmaceutical Inc., two Johnson & Johnson companies. Movetis shares are listed on Euronext Brussels under the ticker MOVE.

    About Quintiles
    Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of 23,000 engaged professionals in more than 50 countries around the globe works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.

    Forward-Looking Statements
    This press release contains “forward-looking statements,” based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from expectations and projections. Risks and uncertainties include, among other things, general industry conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to product marketing, such as the unpredictability of market acceptance for new products; inconsistency of treatment results among patients; the potential for product failures; potential difficulties in manufacturing; governmental laws and regulations affecting domestic and foreign operations and the ongoing success of the collaboration. The parties expressly disclaim any intent or obligation to update these forward-looking statements except as required to do so by law.

    # # #

    Contacts

     

    Greg Connors, Investor Relations
    Office: +1 919 998 2000

    Mari Mansfield, Media Relations
    Office: +1 919 998 2639

    (来源: Quintiles )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, 时时彩网络平台,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


  • 中国资本市场开放出大招 跨境证券投资更便利 2019-10-13
  • 世卫将“游戏障碍”列为新疾病 哪些症状可被确诊? 2019-10-13
  • 景区去门票化积弊短期难除 如何摆脱门票依赖? 2019-10-08
  • 东风路老旧小区欲华丽变身 微改造项目勘察设计已招标 ——凤凰网房产广州 2019-10-08
  • 翔龙无人机服役后首次曝光,大幅提升空军情报收集能力 2019-09-19
  • 证监会去年对外公开监管信息14560条 2019-09-19
  • 人民网欧洲中心分社记者报道集 2019-09-06
  • 图解:短视频平台频遭约谈敲响警钟,野蛮生长要不得! 2019-09-06
  • 中考期间广州部分公交线路有调整 2019-09-01
  • 减肥必备!这十种食物饱口福还能吃出好身材 2019-09-01
  • “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 湖北福彩官网 电子游艺平台白菜网 德国转会市场中文网 2019网络赚钱行业 大乐透第17087开奖号码 国际娱乐公司 搜狐彩票红包 0k000澳客网竞彩 甘肃11选5走势图甘 3d杀号彩经网 17年亿元大奖 中盛重新时时彩 赛马会三肖中特 新疆时时5星走势图星 足球比赛规定